Secondary acute promyelocytic leukemia: An increasingly common entity [4]

Leukemia and Lymphoma

Volumn 48, Issue 1, 2007, Pages 190-191

  Jantunen, E ^a   Heinonen, K ^a   Mahlamaki E ^a   Penttila K ^a   Kuittinen, T ^a   Lehtonen, P ^a   Pyorala M ^a   Hanninen A ^a   Nousiainen, T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MITOGUAZONE; PREDNISOLONE; RETINOIC ACID; RITUXIMAB; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; BREAST SARCOMA; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; HISTIOCYTOSIS; HUMAN; LETTER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; MIDDLE AGED; RADIOTHERAPY; REMISSION; SECOND CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34247231536     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600961736     Document Type: Letter

References (11)

1. de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L. and Dejean, A. (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, 66, pp. 675-686.
2. Pollicardo, N., O'Brien, S., Estey, E. H., al-Bitar, M., Pierce, S., Keating, M. and Kantarjian, H. M. (1996) Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia, 10, pp. 27-31.
3. Beaumont, M., Sanz, M., Carli, P. M., Maloisel, F., Thomas, X. and Detourmignies, L. (2003) Therapy-related acute promyelocytic leukaemia. J Clin Oncol, 21, pp. 2123-2137.
4. Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A. and Cassinat, B. (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukaemia. N Engl J Med, 352, pp. 1529-1538.
5. Fenaux, P., Deley, M C Le, Castaigne, S., Archimbaud, E., Chomienne, C. and Link, H. (1993) Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukaemia: Results of a multicenter randomized trial. Blood, 82, pp. 3241-3249.
6. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H. and Archimbaud, E. (1999) A randomized comparison of all-trans retinoic acid and (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 94, pp. 1192-1200.
7. Tallman, M. S., Nabhan, C., Feusner, J. H. and Rowe, J. M. (2002) Acute promyelocytic leukemia: Evolving strategies. Blood, 99, pp. 759-767.
8. Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A. and Balasubramaniam, P. (2006) Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood, 107, pp. 2627-2632.
9. Alimoghaddam, K., Shariftabrizi, A., Tavanger, M., Sanaat, Z., Rostami, S., Jahani, M. and Ghavamzadeh, A. (2006) Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukaemia. Leuk Lymphoma, 47, pp. 81-88.
10. Raffoux, E., Rousselot, P., Poupon, J., Daniel, M. T., Cassinat, B. and Delarue, R. (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukaemia. J Clin Oncol, 21, pp. 2326-2334.
11. Shigeno, K., Naito, K., Sahara, M., Kobayashi, M., Nakamura, S. and Fujisawa, S. (2005) Arsenic trioxide in relapsed or refractory Japanese patients with acute promyelocytic leukemia: Updated outcomes of the phase II study and postremission therapies. Int J Haematol, 82, pp. 224-229.